A PHASE IV, MULTICENTER, OPEN-LABEL STUDY TO ASSESS CORNEAL ENDOTHELIAL CELLS IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB (PDS)
Latest Information Update: 24 Jan 2024
At a glance
- Drugs Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms Belvedere
- Sponsors Genentech
- 16 Jan 2024 Planned number of patients changed from 58 to 185.
- 16 Jan 2024 Planned End Date changed from 31 Jan 2024 to 30 Apr 2027.
- 16 Jan 2024 Planned primary completion date changed from 31 Jan 2024 to 30 Apr 2027.